|
Market Closed -
Other stock markets
|
After hours 05:59:22 am | |||
| 0.6120 EUR | +13.12% |
|
0.6130 | +0.16% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 11/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 49.8M | |
| 41.9x | 6.19x | -0.73x | 5.41x | 21.1x | 28.12x | 2.61% | 322B | |
| 24.2x | 2.03x | -16.95x | 3.31x | 11.73x | 19.44x | 1.63% | 71.6B | |
| 12.37x | 13x | 0.08x | 6.29x | 9.58x | 10.52x | - | 9.79B | |
| 16.54x | 1.43x | 0.8x | 2.09x | 7.16x | 8.57x | 2.69% | 8.39B | |
| 21.07x | 5.6x | 2.11x | 5.95x | 16.86x | 17.56x | -.--% | 4.3B | |
| 36.85x | 2.38x | -1.58x | 2.28x | 27.77x | 41.28x | 0.76% | 3.81B | |
| 30.75x | - | 0.2x | 5.86x | 16.74x | 27.12x | - | 3.58B | |
| 100.29x | - | -0.61x | - | - | - | -.--% | 2.59B | |
| 63.81x | - | -0.12x | - | - | - | - | 1.27B | |
| 14.88x | 0.78x | -0.87x | 1.14x | 22.35x | 62.01x | 4.16% | 1.06B | |
| -67.77x | 1.64x | 1.02x | - | - | - | - | 913M | |
| Average | 26.81x | 4.13x | -1.51x | 4.04x | 16.66x | 26.83x | 1.69% | 35.74B | |
| Weighted average by Cap. | 37.55x | 5.48x | -3.36x | 4.98x | 18.96x | 25.95x | 2.39% |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
